40 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
10 May 24
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
7:01am
for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be initiated in Q4 2024
Phase 2 clinical trial … with Théa Open Innovation (TOI) put us in a strong position to advance our two retinal programs, KIO-301 and KIO-104, into mid-stage clinical trials
424B3
KPRX
Kiora Pharmaceuticals Inc
28 Mar 24
Prospectus supplement
4:48pm
Open Innovation SAS (“TOI”) with respect to KIO-301. Under the agreement, we granted to TOI an exclusive, sublicensable license to develop, manufacture
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Mar 24
Results of Operations and Financial Condition
7:03am
of non-infectious uveitis. The $16 million upfront payment from Kiora’s development and commercialization partnership with Théa Open Innovation (TOI
8-K
EX-99.1
vcut4l b9
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-99.1
1h3bda44l9
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
mk66eq7drwawy
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-10.1
ywzr 16dw4tpn3ko
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
bno3laajjdjw 48ak6c
21 Sep 23
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
7:00am
8-K
EX-99.1
2nlpf nfwuo
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
424B1
ysg7yfzhtblgphx
2 Jun 23
Prospectus with pricing info
5:08pm
424B3
po0 fcgxm
28 Dec 22
Prospectus supplement
4:48pm
424B1
3t0a6s4
22 Jul 22
Prospectus with pricing info
6:00pm